LU82527A1 - Nouveaux pyridylaminotriazoles et composition pharmaceutique les contenant - Google Patents

Nouveaux pyridylaminotriazoles et composition pharmaceutique les contenant Download PDF

Info

Publication number
LU82527A1
LU82527A1 LU82527A LU82527A LU82527A1 LU 82527 A1 LU82527 A1 LU 82527A1 LU 82527 A LU82527 A LU 82527A LU 82527 A LU82527 A LU 82527A LU 82527 A1 LU82527 A1 LU 82527A1
Authority
LU
Luxembourg
Prior art keywords
amino
triazole
mono
pyridyl
mixture
Prior art date
Application number
LU82527A
Other languages
English (en)
French (fr)
Inventor
C Lipinski
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of LU82527A1 publication Critical patent/LU82527A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/86Hydrazides; Thio or imino analogues thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU82527A 1979-06-18 1980-06-16 Nouveaux pyridylaminotriazoles et composition pharmaceutique les contenant LU82527A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/049,737 US4276297A (en) 1979-06-18 1979-06-18 Pyridylaminotriazole therapeutic agents
US4973779 1979-06-18

Publications (1)

Publication Number Publication Date
LU82527A1 true LU82527A1 (fr) 1981-02-03

Family

ID=21961428

Family Applications (1)

Application Number Title Priority Date Filing Date
LU82527A LU82527A1 (fr) 1979-06-18 1980-06-16 Nouveaux pyridylaminotriazoles et composition pharmaceutique les contenant

Country Status (24)

Country Link
US (1) US4276297A (ko)
JP (1) JPS565477A (ko)
KR (2) KR840002173B1 (ko)
AR (2) AR225766A1 (ko)
AT (2) AT375655B (ko)
BE (1) BE883859A (ko)
CA (1) CA1140133A (ko)
CH (1) CH644375A5 (ko)
DE (1) DE3022302C2 (ko)
DK (1) DK258180A (ko)
ES (2) ES8105313A1 (ko)
FI (1) FI69842C (ko)
FR (1) FR2459241A1 (ko)
GB (1) GB2053910B (ko)
GR (1) GR68731B (ko)
IE (1) IE49913B1 (ko)
IL (1) IL60332A (ko)
IT (1) IT1140993B (ko)
LU (1) LU82527A1 (ko)
NL (1) NL182641C (ko)
PH (1) PH16875A (ko)
PT (1) PT71399A (ko)
SE (1) SE441745B (ko)
YU (2) YU41717B (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR230994A1 (es) * 1981-08-31 1984-08-31 Pfizer Procedimiento para preparar compuesto de 3'-substituido-5'-(2-amino-4-piridil)-1',2',4'-triazol
JP2518515Y2 (ja) * 1993-09-22 1996-11-27 茂郎 槇島 水虫用医療包帯
US9440953B2 (en) * 2014-12-19 2016-09-13 OncoArendi Therapeutics Sp. z o.o. Substituted amino triazoles useful as acidic mammalian chitinase inhibitors
EP4196793A1 (en) 2020-08-11 2023-06-21 Université de Strasbourg H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1925654U (de) 1965-07-23 1965-10-21 Alfons Mann Zusatzeinrichtung fuer vergaser an benzinmotoren zur steigerung der motorenleistung.
CH521419A (de) * 1968-03-01 1972-04-15 Ciba Geigy Ag Verfahren zur Herstellung neuer Azofarbstoffe
GB1264798A (ko) 1968-07-10 1972-02-23
US3647814A (en) * 1969-07-03 1972-03-07 Rohm & Haas Method for preparing 4-substituted-1 2 4-triazoles
NL7112372A (ko) * 1970-09-25 1972-03-28
NL7112373A (ko) * 1970-09-25 1972-03-28
GB1403866A (en) * 1971-12-06 1975-08-28 Wyeth John & Brother Ltd Derivatives of 3-amino-1,2,4-triazoles
US3879404A (en) * 1972-07-07 1975-04-22 John J Baldwin Certain 5-(pyridyl)-3(phenyl)-1,2,4-triazoles
US3873563A (en) * 1972-09-29 1975-03-25 Sakai Chemical Industry Co Method for manufacturing 4-amino-1,2,4-triazoles
US3928361A (en) * 1973-05-21 1975-12-23 Merck & Co Inc 1-(Sulfamoylphenylalkyl)-3,5-dipyridyl-1,2,4 triazoles
US3984558A (en) * 1973-05-21 1976-10-05 Merck & Co., Inc. 1,3,5-Trisubstituted-1,2,4-triazole compounds used as bronchodilators

Also Published As

Publication number Publication date
AR225766A1 (es) 1982-04-30
SE8004498L (sv) 1980-12-19
IL60332A0 (en) 1980-09-16
CH644375A5 (fr) 1984-07-31
FR2459241A1 (fr) 1981-01-09
CA1140133A (en) 1983-01-25
ES498821A0 (es) 1981-12-01
NL182641B (nl) 1987-11-16
KR840002173B1 (ko) 1984-11-26
IL60332A (en) 1983-09-30
IT1140993B (it) 1986-10-10
NL182641C (nl) 1988-04-18
IE49913B1 (en) 1986-01-08
IT8022825A0 (it) 1980-06-17
KR840002172B1 (ko) 1984-11-26
IE801250L (en) 1980-12-18
ATA307583A (de) 1984-01-15
AT375656B (de) 1984-08-27
FR2459241B1 (ko) 1983-06-17
DK258180A (da) 1980-12-19
YU41536B (en) 1987-08-31
GB2053910B (en) 1983-04-20
FI69842C (fi) 1986-05-26
KR840004687A (ko) 1984-10-22
ES492522A0 (es) 1981-06-01
DE3022302C2 (de) 1984-03-01
FI801929A (fi) 1980-12-19
YU263382A (en) 1983-04-30
BE883859A (fr) 1980-12-17
GB2053910A (en) 1981-02-11
YU158780A (en) 1983-04-30
DE3022302A1 (de) 1981-01-08
FI69842B (fi) 1985-12-31
ATA319280A (de) 1984-01-15
KR830002756A (ko) 1983-05-30
AR227436A1 (es) 1982-10-29
YU41717B (en) 1987-12-31
JPS565477A (en) 1981-01-20
ES8201155A1 (es) 1981-12-01
PH16875A (en) 1984-04-02
US4276297A (en) 1981-06-30
ES8105313A1 (es) 1981-06-01
PT71399A (en) 1980-07-01
JPS617426B2 (ko) 1986-03-06
SE441745B (sv) 1985-11-04
AT375655B (de) 1984-08-27
NL8003496A (nl) 1980-12-22
GR68731B (ko) 1982-02-10

Similar Documents

Publication Publication Date Title
KR100371297B1 (ko) 치환된티아졸리딘디온유도체
KR100353783B1 (ko) 마그네슘오메프라졸
EP1956015B2 (en) Polymorph of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same
AU752764B2 (en) Crystal form of N-(4-trifluoromethylphenyl)-5- methylisoxazole-4-carboxamide
EP0571253B1 (fr) Dérivés du benzimidazole à activité antidiabétique et antiagrégante plaquettaire
BE898278A (fr) Benzoxazines antipsychotiques.
MXPA05002251A (es) Polimorfo novedoso del n- metil -n- (3- {3-[2- tienilcarbonil] -pirazol -[1, 5-(alfa)] -pirimidina- 7-yl} fenil) acetamida y composiciones y metodos relacionados.
FR2489823A1 (fr) Nouvelles n-((4-(3-pyridyle substitue en position 3)-piperazino)alkyl)azaspirodecanediones, leur procede de preparation et medicament les contenant
LU80458A1 (fr) Nouveaux derives de phtalazine,leur procede de production,et composition pharmaceutique les contenant
NO329315B1 (no) Krystallmodifikasjon av forbindelse, farmasoytiske preparater inneholdende denne og anvendelse av krystallmodifikasjonen.
FR2526434A1 (fr) Nouveaux azepino-indoles, leur preparation et leur utilisation comme medicaments
LU82527A1 (fr) Nouveaux pyridylaminotriazoles et composition pharmaceutique les contenant
FR2580282A1 (fr) Derives a cycle imidique de 2-(4-butylpiperazine-1-yl)pyridines et leur application antipsychotique
EP0156734A2 (fr) Triazolo[4,3-b]pyridazines, procédé pour leur préparation et compositions pharmaceutiques les contenant
KR860000103B1 (ko) 3'-치환-5'-(2-아미노-4-피리딜)-1', 2', 4'-트리아졸류의 제조 방법
JPH06192228A (ja) 結晶性(r)−(−)−2−シクロヘプチル−n−メチルスルフオニル−[4−(2−キノリニルメトキシ)−フエニル]−アセトアミド
FR2483233A1 (fr) Compositions cardiotoniques contenant des aminophenylpyridines, nouvelles aminophenylpyridines et leur preparation
LU83032A1 (fr) 3-acylamino-5(pyridinyl)-2(1h)-pyridinones,leur preparation et leur utilisation comme agents cardiotoniques
CH642953A5 (fr) Derives acyles de ih-1,2,4-triazole, leur utilisation et procede de synthese desdits derives.
LU82546A1 (fr) Derives du benzimidazole et compositions pharmaceutiques les contenant
FR2460950A1 (fr) Nouvelles 4-phenyl-4,5,6,7-tetrahydropyrrolo(2,3-c)pyridines, procede pour leur preparation et medicaments les renfermant
JP2003206229A (ja) ファモチジン多形体aとbとの混合物の製造方法
BE831758A (fr) Derives de substitution de 2h-pyrane-2,6 (3h)-dione et leurs utilisations
FR2494690A1 (fr) Derives de (pyridinyl)benzene, leur preparation et leur utilisation comme agents cardiotoniques
FR2967413A1 (fr) Compose 8-oxo-9-[3-(1h-benzimidazol-2-yloxy)-phenyl]-4,5,6,7,8,9-hexahydro-2h-pyrrolo[3,4-b]quinoline-3-carboxylate d'ethyle, sel, forme cristalline, co-cristal, formulation, procedes de preparation, application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteur des kinases aurora.